stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
RESEARCH GREYP-065
Recovery

VEGF (Vascular Endothelial Growth Factor)

Angiogenic glycoprotein. Drives endothelial cell proliferation + capillary network formation at wound + ischemic tissue sites. The mechanism behind 'better blood supply heals faster.'

ExperimentalRecovery
Typical doseTopical: ppm-level in serum formulations
Frequencytwice daily, topical
Half-life0.5h
Citations indexed52
100%50%0%030min1h1.5h2h2.5ht½ 30minPK · plasma

How it clearsHalf cleared in ~30min. Most (~96%) gone by ~2.5h.

DeliveryInjectable
Half-life~30min
EvidenceExperimental
Citations52
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompareReconstitution calc
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

Best-known therapeutically as the TARGET of anti-VEGF drugs (bevacizumab, ranibizumab) for cancer + macular degeneration — blocking VEGF starves tumors + stops abnormal retinal vasculature. Pro-VEGF therapeutic use (driving angiogenesis at wound sites) exists in regenerative medicine but is research-grey. The cancer-promotion concern via tumor angiogenesis is the central caveat. Blueprint Serum includes VEGF — the topical formulation operates well below systemic exposure that would drive tumor risk.

Specifics
Slow wound healingSkin agingSoft-tissue injury / tendon
Caveats

Tumor-angiogenesis is the dominant safety concern. Contraindicated in any patient with active malignancy or recent cancer history. Topical formulations claim to operate locally without systemic exposure — verify formulation specifics. Theoretical concern for promoting growth of pre-clinical malignant cells via systemic angiogenic signaling.

Evidence levelExperimental
Regulatory statusAnti-VEGF drugs FDA-approved · pro-VEGF therapeutic + cosmetic use is research-grey
DNA / pharmacogenomicsLow — VEGFA polymorphisms theoretically modulate; PG not actionable for grey-market dosing.
Your data · empty

Upload your data to see how it relates to VEGF.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • DMechanistic / anecdotal

    VEGF (Vascular Endothelial Growth Factor) — primary mechanism: angiogenic glycoprotein. drives endothelial cell proliferation + capillary network formation at wound + ischemic tissue sites. the mechanism behind 'better blood supply heals faster.'

    2 supporting referencesVerified 13d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    REVIEWFunding undisclosedVerified 13d ago
    PubMed — VEGF wound healing angiogenesis
  • PubMedEN
    REVIEWFunding undisclosedVerified 13d ago
    PubMed — pro-VEGF regenerative therapy review
RESEARCH GREYP-065

Anti-VEGF drugs FDA-approved · pro-VEGF therapeutic + cosmetic use is research-grey

Can I get it? →
Reconstitution calculatorVEGF

Pre-filled with this compound's published dose range: Topical: ppm-level in serum formulations · twice daily, topical

Concentration2.50 mg/mL
Draw volume0.100 mL
Insulin syringe10.0 u
Doses per vial20
U-100 syringe — fill to indicatorU-100 · 1 mL
0u25u50u75u100u

Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.

No field reports yet

Field reports are added as users share their real-world protocols.

VEGFTopical: ppm-level in serum formulations · twice daily, topical

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe